Convertissez Collies COLLIES en VitaStem VITASTEM

Welcome to $COLLIES, the pioneering community-driven token crafted for dog lovers everywhere, with a special place in its heart for fans of the intelligent and loyal Border Collie. $COLLIES is more than just a cryptocurrency—it’s a movement that unites the timeless values of loyalty, passion, and companionship with the limitless possibilities of blockchain innovation. In a world where technology and emotion often feel worlds apart, $COLLIES stands as a bridge, bringing together people who cherish their furry companions and those who believe in the transformative power of decentralized finance. At its core, $COLLIES is about celebrating the unique bond between humans and dogs. Inspired by the Border Collie’s legendary intelligence, agility, and devotion, our project seeks to create a digital ecosystem where every member feels valued, empowered, and connected. Whether you’re a lifelong dog owner, an NFT enthusiast, or a newcomer to the world of crypto, you’ll find a welcoming pack in the $COLLIES community.

VitaSTEM — The first AI-enabled longevity project and inaugural IP-Token launched by Aubrai, VitaDAO’s decentralized scientific agent. After six months of deep research on public and proprietary single-cell RNA-seq and multi-omics datasets, our scientific research team analyzed more than 850,000 human hematopoietic stem cell transcriptomes from donors aged 23–91 (both male and female). This effort uncovered 100+ high-potential rejuvenation target genes and revealed critical drivers of decline such as RhoA hyperactivation, CD38 upregulation, and CCR9 downregulation. Rather than treating HSC aging as a single defect, Aubrai recognized it as convergent damage across interconnected systems, generating a comprehensive multi-modal, five-phase rejuvenation protocol targeting transcriptional stress, metabolic dysfunction, and epigenetic drift in parallel. The agent shortlisted target genes using insights from thousands of peer-reviewed publications and private data and also optimized experimental protocols to guide in vitro and upcoming pre-clinical testing. For the first time, human researchers and AI Agents collaborate as co-scientists in the creation of pioneering scientific IP.